Meningitis is fatal but rare. It refers to any type of inflammation of the membranous tissues layer encapsulating the brain and spinal cord, also known as the meninges. Meningococcal meningitis is caused by various aerobic Gram-negative bacteria known as Neisseria meningitidis or meningococcus. Meningitis is often spread through close direct contact with carriers. It is susceptible in children or adolescents between 3 and 12 months1. CDC recommended that serogroup B meningococcal vaccine is optional for healthy teens aged 16 to 18 years old2.
Group A and C Meningococcal Polysaccharide Vaccine, Polysaccharide
Meningococcal meningitis and septicaemia are caused by various serogroups of Neisseria meningitidis (meningococcus) which is an aerobic Gram-negative encapsulated bacteria. At least 12 serotypes of meningococcus have been characterized by differences in the polysaccharide capsule, of which groups A, B and C account for about 90% of meningococcal disease. N. meningitidis is one of the most common causes of bacterial meningitis in the world and the only bacterium capable of generating large epidemics of meningitis. Meningococcal vaccines containing unconjugated purified capsular polysaccharides (A, C, Y and W) have been available since the 1970s and are still used to immunise travellers and at risk individuals.
Our vaccine is the bivalent vaccine which include A and C polysaccharides.
The COVID-19 pandemic has underscored the importance of research and development in preparation for future pandemics. In Sino-Innovax, we focus on predicting new infectious landscapes and challenge the frontiers of vaccine science. We are open to collaboration with innovative and cutting-edge technologies and products which align with our strategic interest.
Plasma being the largest component in the human blood, helps individuals to stay healthy. Plasma-derived products are prepared from the separation of proteins in the human plasma and are vital in the treatment of autoimmune diseases. a. Human Immunoglobulin (pH4) for Intravenous Injection IVIG targets a wide range of autoimmune diseases […]
Our parent company China National Biotec Group (CNBG) is the 6th largest vaccine manufacturer in the world. CNBG has the capacity of manufacturing approximately 700 million doses of 50 various human vaccines (a year?) Sino-Innovax is also committed to benefit people from all around the globe through our constant development of efficient and novel vaccines. […]